Our portfolio

CEPI has initiated 9 partnerships to develop vaccines against COVID-19. The programs will leverage rapid response platforms already supported by CEPI as well as new partnerships. The aim is to advance COVID-19 vaccine candidates into clinical testing as quickly as possible.

Before the emergence of COVID-19, CEPI's priority diseases included Ebola virus, Lassa virus, Middle East Respiratory Syndrome coronavirus, Nipah virus, Rift Valley Fever and Chikungunya virus. CEPI also invested in platform technologies that can be used for rapid vaccine and immunoprophylactic development against unknown pathogens (Disease X).

Filter by:

PRODUCT DEVELOPERS

All
Auro Vaccines & PATH
Clover Biopharmaceuticals
Colorado State University
CureVac
Emergent Biosolutions & PATH
IDT Biologika
Imperial College London
Inovio Pharmaceuticals
Institut Pasteur, Themis Bioscience, University of Pittsburgh
International AIDS Vaccine Initiative
International Vaccine Institute and Bharat Biotech
Janssen Vaccines & University of Oxford
Moderna, Inc.
Novavax, Inc.
Public Health Vaccines
Themis Bioscience
University of Hong Kong
University of Oxford and Astrazeneca
University of Queensland
University of Tokyo
Valneva SE
Wageningen Bioveterinary Research

DISEASE

All
Chikungunya
COVID-19
Lassa virus
Marburg virus
MERS coronavirus
Nipah virus
Rift Valley Fever

VACCINE TYPE

All
ChAdOx1
HeV-sG-V vaccine
Inactivated Whole Virion vaccine
Live attenuated vaccine
Measles vector
Nucleic acid
Recombinant protein
Recombinant protein nanoparticle technology
Recombinant viral vector
S-Trimer vaccine

PHASE

All
Phase 1
Phase 1/2
Phase 3
Preclinical

Filter by product developers:

All
Auro Vaccines & PATH
Clover Biopharmaceuticals
Colorado State University
CureVac
Emergent Biosolutions & PATH
IDT Biologika
Imperial College London
Inovio Pharmaceuticals
Institut Pasteur, Themis Bioscience, University of Pittsburgh
International AIDS Vaccine Initiative
International Vaccine Institute and Bharat Biotech
Janssen Vaccines & University of Oxford
Moderna, Inc.
Novavax, Inc.
Public Health Vaccines
Themis Bioscience
University of Hong Kong
University of Oxford and Astrazeneca
University of Queensland
University of Tokyo
Valneva SE
Wageningen Bioveterinary Research

Filter by disease:

All
Chikungunya
COVID-19
Lassa virus
Marburg virus
MERS coronavirus
Nipah virus
Rift Valley Fever

Filter by vaccine type:

All
ChAdOx1
HeV-sG-V vaccine
Inactivated Whole Virion vaccine
Live attenuated vaccine
Measles vector
Nucleic acid
Recombinant protein
Recombinant protein nanoparticle technology
Recombinant viral vector
S-Trimer vaccine

Filter by phase:

All
Phase 1
Phase 1/2
Phase 3
Preclinical

N/A

No result